Showing results (871-880 of 6,317) with videos related to

Sort By:
Pageof 632
Diabetes, Obesity & Metabolism|February 2, 2021
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trialClare A Whicher, Hermione C Price, Peter Phiri, et al.
Diabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand Cariou
Diabetes, Obesity & Metabolism|December 6, 2021
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trialsEsteban Jódar, Irene Romera, Qianqian Wang, et al.
Diabetes, Obesity & Metabolism|January 4, 2022
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trialsLawrence A Leiter, Maciej Banach, Alberico L Catapano, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairmentJuris J Meier, Daniel R Quast, Michael A Nauck, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension periodCaroline Reilhac, Julie Dubourg, Carole Thang, et al.
Diabetes, Obesity & Metabolism|November 15, 2021
Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortalityAmna Alhakak, Jawad H Butt, Thomas A Gerds, et al.
Diabetes, Obesity & Metabolism|November 15, 2021
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trialsAjay Chaudhuri, Husam Ghanim, Pradeep Arora
Diabetes, Obesity & Metabolism|December 27, 2021
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetesJuris J Meier, Charlotte Granhall, Ulrike Hoevelmann, et al.
Diabetes, Obesity & Metabolism|October 31, 2022
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot resultsDaria Igudesman, Jamie Crandell, Karen D Corbin, et al.
Pageof 632